PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1). (23rd June 2022) - DeZern, A.; Marconi, G.; Deeren, D.; Diez Campelo, M.; Lübbert, M.; Krishnamurthy, P.; Nagy, Z.; Basak, G.; Jonášová, A.; Morozova, E.; Geissler, K.; Ofran, Y.; et al.